Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian equity markets trade in green
Wed, 5 Jun 01:30 pm

Indian equity markets have recovered some losses and are trading above the dotted line during the post noon trading session. Most noticeable upward movement is being noticed in the stocks from oil & gas and realty sector, however stocks from the IT and FMCG sectors are witnessing maximum selling pressure.

BSE-Sensex is up by 36 points and NSE-Nifty is trading down up by 8 points. While BSE Mid Cap is trading up by 0.12%, BSE Small Cap index is trading up by 0.22%. The rupee is trading at 56.50 to the US dollar.

FMCG stocks are trading mixed with Jyothy Consumer and Emami being the major gainers and P&G Hygiene and Godrej Consumer Products (GCPL) being the biggest losers. As per a leading financial daily, GCPL is contemplating entering the salon business and is reportedly in talks with Mumbai-based hair dressing and salon chain b:blunt. However, the company wants to enter the salon business more in terms of the salon brand rather than a service offering. The company already has a niche hair styling global brand - Salon Selectives that it has added to its portfolio through the acquisition of UK based Keyline Brands in 2005. This brand competes with other salon brands such as L'Oreal and Schwarzkopf and has a line of hair care products ranging from shampoos, hair conditioners, mousses, sprays, gels and oils. The company is exploring the possibility of introducing the Salon Selective brand that recently became a part of the Keyline Brands portfolio.

Domestic pharma stocks are trading mixed with, Elder Pharma and Sun Pharma leading among gainers while Cadila Healthcare and JB Chemicals are the major losers. Cadila has recently announced that the company has achieved a significant milestone for Lipaglyn drug in its research and development pipeline. The said drug will be first NCE (new chemical entity) to reach Indian markets. This is the world's first drug for treating diabetic dyslipidemia. The drug combines lipid and glucose lowering effects in one single molecule. The drug has been approved for launch in India by DCGI (Drug Controller and General of India). Diabetic Dyslipidemia is a condition where a person is diabetic and has elevated levels of cholesterol. India has a population of approximately 65 m diabetics and 77 m pre-diabetics. Above 85% of patients suffer dylipidemia abnormalities. Cadila was trading down by 4%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian equity markets trade in green". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.